Cargando…

Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer

BACKGROUND: Lung squamous cell cancer in situ (LSCIS) is preinvasive squamous tumor and generally overlooked as a potential subtype of pathological and clinical significance, which has seldom been investigated systematically. This study sought to explore the clinical features, prognostic factors, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kaixuan, Chen, Hao, Jiang, Yan, Chen, Qiankun, Su, Bo, Zhou, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326786/
https://www.ncbi.nlm.nih.gov/pubmed/37425404
http://dx.doi.org/10.21037/tlcr-23-243
_version_ 1785069494965633024
author Zhang, Kaixuan
Chen, Hao
Jiang, Yan
Chen, Qiankun
Su, Bo
Zhou, Xiao
author_facet Zhang, Kaixuan
Chen, Hao
Jiang, Yan
Chen, Qiankun
Su, Bo
Zhou, Xiao
author_sort Zhang, Kaixuan
collection PubMed
description BACKGROUND: Lung squamous cell cancer in situ (LSCIS) is preinvasive squamous tumor and generally overlooked as a potential subtype of pathological and clinical significance, which has seldom been investigated systematically. This study sought to explore the clinical features, prognostic factors, and optimal treatments for LSCIS patients. METHODS: Patients diagnosed with LSCIS (n=449), lung adenocarcinoma in situ (LAIS; n=1,132), stage IA lung squamous cell cancer (LSQCC; n=22,289) and stage IA lung adenocarcinoma (LUAD; n=68,523) were identified in the Surveillance Epidemiology and End Results (SEER) database. Additionally, 512 patients from the Shanghai Pulmonary Hospital diagnosed with LSCIS (n=34), LAIS (n=248), stage IA LSQCC (n=118) and stage IA LUAD (n=112) were included in the study. Kaplan-Meier survival curves were constructed, and Cox proportional hazards regression analyses were performed to examine the overall survival (OS), lung cancer-specific survival (LCSS), and progression-free survival (PFS) of the patients. RESULTS: The univariate and multivariate analyses showed the patients with LSCIS had significantly worse survival than those with LAIS. Although, the univariate analysis revealed that the LSCIS patients had significantly worse OS and LCSS than the stage IA LSQCC patients, the multivariate analyses showed that the prognosis of the LSCIS was similar to that of the stage IA LSQCC in the SEER cohort. The prognosis of the LSCIS was similar to that of the stage IA LSQCC in the Shanghai Pulmonary Hospital cohort. The univariate and multivariate analyses showed that age (>70 years) and chemotherapy were negative prognostic factors, and surgery was a favorable prognostic factor for the LSCIS patients. The survival of the LSCIS patients who underwent local tumor destruction or excision was similar to that of those who did not receive surgery. Lobectomy was the surgical procedure associated with the highest OS and LCSS in LSCIS patients. CONCLUSIONS: The survivals of the LSCIS were similar to those of the stage IA LSQCC, but significantly worse than those of the LAIS. Surgery was an independent favorable prognostic factor for the LSCIS patients. Lobectomy was a superior choice of surgical procedure, and significantly improved the current outcomes of the LSCIS patients.
format Online
Article
Text
id pubmed-10326786
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-103267862023-07-08 Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer Zhang, Kaixuan Chen, Hao Jiang, Yan Chen, Qiankun Su, Bo Zhou, Xiao Transl Lung Cancer Res Original Article BACKGROUND: Lung squamous cell cancer in situ (LSCIS) is preinvasive squamous tumor and generally overlooked as a potential subtype of pathological and clinical significance, which has seldom been investigated systematically. This study sought to explore the clinical features, prognostic factors, and optimal treatments for LSCIS patients. METHODS: Patients diagnosed with LSCIS (n=449), lung adenocarcinoma in situ (LAIS; n=1,132), stage IA lung squamous cell cancer (LSQCC; n=22,289) and stage IA lung adenocarcinoma (LUAD; n=68,523) were identified in the Surveillance Epidemiology and End Results (SEER) database. Additionally, 512 patients from the Shanghai Pulmonary Hospital diagnosed with LSCIS (n=34), LAIS (n=248), stage IA LSQCC (n=118) and stage IA LUAD (n=112) were included in the study. Kaplan-Meier survival curves were constructed, and Cox proportional hazards regression analyses were performed to examine the overall survival (OS), lung cancer-specific survival (LCSS), and progression-free survival (PFS) of the patients. RESULTS: The univariate and multivariate analyses showed the patients with LSCIS had significantly worse survival than those with LAIS. Although, the univariate analysis revealed that the LSCIS patients had significantly worse OS and LCSS than the stage IA LSQCC patients, the multivariate analyses showed that the prognosis of the LSCIS was similar to that of the stage IA LSQCC in the SEER cohort. The prognosis of the LSCIS was similar to that of the stage IA LSQCC in the Shanghai Pulmonary Hospital cohort. The univariate and multivariate analyses showed that age (>70 years) and chemotherapy were negative prognostic factors, and surgery was a favorable prognostic factor for the LSCIS patients. The survival of the LSCIS patients who underwent local tumor destruction or excision was similar to that of those who did not receive surgery. Lobectomy was the surgical procedure associated with the highest OS and LCSS in LSCIS patients. CONCLUSIONS: The survivals of the LSCIS were similar to those of the stage IA LSQCC, but significantly worse than those of the LAIS. Surgery was an independent favorable prognostic factor for the LSCIS patients. Lobectomy was a superior choice of surgical procedure, and significantly improved the current outcomes of the LSCIS patients. AME Publishing Company 2023-06-12 2023-06-30 /pmc/articles/PMC10326786/ /pubmed/37425404 http://dx.doi.org/10.21037/tlcr-23-243 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhang, Kaixuan
Chen, Hao
Jiang, Yan
Chen, Qiankun
Su, Bo
Zhou, Xiao
Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
title Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
title_full Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
title_fullStr Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
title_full_unstemmed Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
title_short Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
title_sort treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage ia lung squamous cell cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326786/
https://www.ncbi.nlm.nih.gov/pubmed/37425404
http://dx.doi.org/10.21037/tlcr-23-243
work_keys_str_mv AT zhangkaixuan treatmentoptionsandprognosisofpatientswithlungsquamouscellcancerinsituacomparativestudyoflungadenocarcinomainsituandstageialungsquamouscellcancer
AT chenhao treatmentoptionsandprognosisofpatientswithlungsquamouscellcancerinsituacomparativestudyoflungadenocarcinomainsituandstageialungsquamouscellcancer
AT jiangyan treatmentoptionsandprognosisofpatientswithlungsquamouscellcancerinsituacomparativestudyoflungadenocarcinomainsituandstageialungsquamouscellcancer
AT chenqiankun treatmentoptionsandprognosisofpatientswithlungsquamouscellcancerinsituacomparativestudyoflungadenocarcinomainsituandstageialungsquamouscellcancer
AT subo treatmentoptionsandprognosisofpatientswithlungsquamouscellcancerinsituacomparativestudyoflungadenocarcinomainsituandstageialungsquamouscellcancer
AT zhouxiao treatmentoptionsandprognosisofpatientswithlungsquamouscellcancerinsituacomparativestudyoflungadenocarcinomainsituandstageialungsquamouscellcancer